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THERE are well documented studies
which show that host factors in the mouse
are important determinants of tumour
radiosensitivity (Cohen & Cohen, 1956;
Haddow & Alexander, 1964; Powers et al.,
1967; Maruyama, 1967; Suit & Kastelan,
1970). However, the biological mechanism
which effects this improved response is not
clearly understood (Song & Levitt, 1975;
Johnson, 1978).
As part of an investigation of the inter-
action of X-rays and immune cytotoxicity
in tumour control, an experimental mouse
model system (Porteous et al., 1976) has
been used in which quantitative anti-
tumour immunity was raised in prospec-
tive recipients of tumour-cell suspensions
exposed to varying doses of X-rays in
vitro before injection. Here we report
findings which indicate that, whilst X-rays
kill a proportion of cells, induced im-
munity deals with a fixed number de-
pendent upon the immune status of the
host, and that X-rays and anti-tumour
immunity do not act synergistically in
tumour-cell killing.
The tumour used was the ascites sar-
coma BP8, and experiments were per-
formed between weekly Passages 268 and
315 of the tumour in inbred 10-12-week-
old DMC/Ps mice. Anti-tumour immunity
was assessed by a terminal dilution
method (Hewitt & Wilson, 1959) to give
TD50 (the number of viable tumour cells
required to trasmit the tumour and give
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rise to lethal growth in 50% of the
animals). SD50 (Maruyama, 1967), the
radiation dose to a challenge of tumour
cells required to prevent tumour takes in
half of recipients, was estimated using
mice carrying measured amounts of anti-
tumour immunity.
It has previously been demonstrated
that reproducible immunity against viable
BP8 cell challenge can be obtained in mice
after i.p. inoculation of lethally irradiated
(LI) BP8 cells (Porteous & Munro, 1972).
In the present experiments, cells were
taken from exponentially growing tumours
and counted in a haemacytometer using
phase-contrast microscopy. Cells for im-
munization were prepared by exposing a
suspension of 108 cells/ml in Eagle's
minimum essential medium with 2u/ml
heparin (HMEM) in an atmosphere of95%
air: 5% CO2 to 5000 rad 250 kV X-rays at
a dose rate of 281 rad/min (0.5 mm Cu+1
mm Al filtration). Suitable dilutions were
then made in HMEM to give the desired
LI cell number in 1 ml, which was inocu-
lated as a single dose i.p. into 35-40 male
or female mice. Controls were given
HMEM only. A fortnight later groups of
5-6 immunized or control mice were
challenged i.p. with numbers of viable
cells increasing by factors 101/2 (i.e. 3-16)
to cover the range 0-100% survival. TD50
was estimated using probit transformation
(Finney, 1962) to linearize the relationship
between percent survivors at 90 days after
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challenge and the logarithm of the viable-
cell challenge dose. These coordinates
were fitted to a linear relationship using
weighted mean squares, the weights being
given by maximum-likelihood techniques
(Finney, 1964). The heterogeneity of the
relationship was checked by the chi-
squared test and, as this was more than
80% in all cases, the standard error in this
estimator was calculated as suggested by
Finney. The calculations were made with
a specially written computer programme
which made use of the techniques de-
scribed.
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be the time of maximum host response.
When viable cells and LI cells were in-
jected simultaneously at Time 0, more
than 4 x 105 LI cells had to be given
before measurable immunity could be
detected (unpublished). This finding made
it possible to obtain a radiation dose-
response curve for BP8 cells down to
surviving fractions as small as at least
10-4 without immune interference, by
using the method of Hewitt & Wilson
(1959) in normal female mice. The survival
curve is shown in Fig. 2. It has Do=87
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Lethally irradiated BP8 cells
inoculated i.p. at minus 14 days
FIG. 1. Median lethal dose (TD50) of viable
BP8 ascites sarcoma cells in male (-) or
female (0) mice inoculated with lethally
irradiated (LI) BP8 cells or control males
(LII) or females (0) given HMEM 14 days
earlier. Values are mean TD50s and bars
represent s.e.
It can be seen in Fig. 1 that the TD50
for BP8 cells injected into control females
is 15*86+4*4, that for males is 76-4±16-08,
and that the logarithm of TD50 rises pro-
gressively with the logarithm of the LI-
cell inoculum. At least 104 LI cells are
needed to give measurable immunity. All
tests in this study were made 14 days after
LI-cell injection, since this was found to
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FIG. 2.-X-ray dose-response curve for BP8
ascites sarcoma cells irradiated in vitro and
tested in normal control female mice. TD50
of X-irradiated and unirradiated BP8 cells
were estimated, and surviving fraction (-)
was given by:
TD50 for unirradiated BP8 cells
TD50 for BP8 cells given the X-ray dose
indicated at 100 rad/min in vitro
Bars represent s.e.
rad and extrapolation number, n 4 7 The
radiosensitivity of BP8 cells, expressed as
Do, is similar to the value of 95 rad found
when the cells were tested in vitro (Munro
& Porteous, 1972).
The combined effect of X-rays and
immunity on tumour-cell killing was in-
vestigated by measuring SD50 for 2 x 105
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cells, a number below the experimentally
derived threshold in control animals above
which immune influences were exerted.
Experiments were designed with 60-75
micewhichwere given selectedimmunizing
doses of LI cells and used 14 days later in
subgroups of 5-6 as recipients for either
TD50 or SD50 estimations. TD50s were
quantitated as already described with
the addition of appropriate numbers of LI
cells to give uniform inocula of 2 x105.
Cells for SD50 were obtained by irradiating
a suspension of cells at a concentration of
107/ml in vitro with increasing doses of
X-rays at 100 rad/min in an atmosphere
of95% air: 5% C02. After each irradiation
0.5 ml of cells was removed and dilutions
were made to give the challenge dose of
2x 105 cells in 0*5 ml. X-ray doses were
chosen to give a range of survival of
0-100% in groups of recipients. SD50 was
estimated using probit transformation to
linearize the relationship between percent
survivors of90 days and the dose ofX-rays
given to the challenge dose of cells.
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FiG. 3.-50% challenge-sterilization dose of
X-rays (SD50) for 2x 105 BP8 ascites
sarcoma cells X-irradiated in vitro and
tested in vivo in groups of recipient mice
with varying amounts of induced im-
munity, expressed as TD50. The line was
drawn by least squares and bars represent
s.e.
In Fig. 3 SD50 is plotted with the corres-
ponding TD50 obtained in the same ex-
periment. SD50 was 975 rad when non-
immune control mice were the recipients
ofthe challenge of 2 x 105 cells, whereas it
was reduced to 215 rad when tested in
groups ofmice with TD50 of 5-4 x 104 cells.
A line drawn through the points by least
squares shows that SD50 was reduced by
200 rad for each successive 10-fold in-
crease of TD50 in recipients. The slope of
the line is similar to that of the survival
curve obtained by testing BP8 cells in vivo
(Fig. 2). Thus it is implied that the
destruction of viable BP8 cells by im-
munity is independent of the process of
their depletion by X-rays.
In these experiments we have demon-
strated that, provided the number of
viable cells remaining after the propor-
tional cell killing by X-rays is smaller than
the number against which the recipient
mouse is shown to be immune, the animal
survives. Also, since the total cell killing is
not greater than the sum of that attribut-
able to the two agencies taken separately,
there is no synergistic interaction.
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